Genomics, Biotech & Emerging Medical
The newest CME presentations
are at the top of this page.
Those nearing expiration are nearer the bottom of the page.
|Business/Practice Management||Preventive Health & Lifestyle Medicine||Chronic Illness|
|Behavioral Health||Oncology||Genomics, Biotech & Emerging Medical Technologies|
Overcoming Challenges in the
Emerging Biosimilar Landscape
Biologic agents have revolutionized the treatment of many diseases, including cancer, diabetes, hepatitis, inflammatory bowel disease, and rheumatoid arthritis. A biosimilar is a biologic drug that is developed to be highly similar, but not identical, to an existing biologic. Although there are minor differences in clinically inactive components, they cannot have a clinically meaningful difference between the biological product and the reference product in terms of the safety, efficacy and potency. Along with their sensitivity and size, biologic medicines are almost always injected into a patientís body and the way a patient responses to that treatment can depend on how a biologic is made. Since the complexity of biologic medicines is well documented along with their complex production, biosimilars must be determined on the basis of analytical, non-clinical and clinical data to be similar to an original biologic in structural characteristics, safety and efficacy. Small differences with the active ingredient are expected and permitted so long as any such differences are demonstrated not to be clinically meaningful. Now, with patents continuing to expire on these first biologics, biosimilar products are becoming available. These agents are expected to have a significant impact on healthcare but present a unique set of challenges for regulators, clinicians, payers, and consumers.
Physician, Nursing and CMCN credits valid to January 31, 2018
Immunotherapy and Cancer
Cancer immunotherapy is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid (active and passive). These approaches exploit the fact that cancer cells often have molecules on their surface that can be detected by the immune system, known as tumourassociated antigens (TAAs); they are often proteins or other macromolecules (e.g. carbohydrates). Active immunotherapy directs the immune system to attack tumor cells by targeting TAAs. Passive immunotherapies enhance existing anti-tumor responses and include the use of monoclonal antibodies, lymphocytes and cytokines. Advances in the understanding of the immune system are changing the way the interprofessional healthcare team manages cancer. As immunotherapies move to the forefront of cancer treatment, healthcare professionals will need to understand the immune system; know how cancer circumvents it; and be aware of the mechanisms of action, efficacy, and safety of current and emerging immunotherapies.
The development of immunotherapies to treat cancer has transformed the way clinicians think about managing their patients with many forms of malignancies. The speed, at which basic science and clinical trial information continues to emerge in this area, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.
Physician, Nursing and CMCN credits valid to December 31, 2017
Exploring the Recent Advances of
Since the complexity of biologic medicines is well documented along with their complex production, biosimilars must be determined on the basis of analytical, non-clinical and clinical data to be similar to an original biologic in structural characteristics, safety and efficacy. Small differences with the active ingredient are expected and permitted so long as any such differences are demonstrated not to be clinically meaningful. The patents of a growing number of biologic medicines have already expired and will continue to expire, which has led to an increased interest in the development of biosimilars. With patents expiring over the next several years, we will continue to see a new generation of complex biosimilars being developed as numerous leading biologic medicines, worth an estimated $81 billion in global annual sales.
Physician, Nursing and CMCN credits valid to July 31, 2017
Virtual Health Assistants:
Potentially the Most Strategically Disruptive Technology in My
Technology is in every part of all of our lives. Healthcare professionals are looking at ways to improve adherence and patient outcomes through technology. Will avatars or virtual assistants be the way?